Bio-Rad Laboratories, Inc.（BIO.B）のニュースとイベントBIO.BBio-Rad Laboratories, Inc.

Bio-Rad rises 15.8%

Bio-Rad is up 15.8%, or $38.23 to $280.18.

Bio-Rad sees FY25 non-GAAP, currency-neutral revenue growth of flat to up 1%

Bio-Rad is updating its financial outlook for the full year 2025. The company currently expects non-GAAP, currency-neutral revenue growth of approximately 0 to 1.0 percent versus its prior estimated range of approximately a 1.0 percent decline to 1.5 percent growth. Non-GAAP operating margin is now estimated to be approximately 12.0 to 13.0 percent compared to the company's prior expectation of approximately 10.0 to 12.0 percent.

Bio-Rad reports Q2 adjusted EPS $2.61, consensus $1.75

Reports Q2 revenue $651.6M, consensus $614.29M. Norman Schwartz, Bio-Rad's Chairman and Chief Executive Officer, stated: "In a highly dynamic environment, we delivered solid quarterly results, both in terms of revenue and operating margin, through focused execution and careful expense management. We also completed the acquisition of droplet digital PCR developer Stilla Technologies, effectively expanding our Droplet Digital PCR offering with the recent launch of our QX Continuum system complemented by the QX700 series of acquired instruments."